Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test
Immunovia (IMMNOV), a pancreatic cancer diagnostics company, announced a webcast scheduled for December 17, 2024, at 3 pm CET to discuss the positive clinical validation results of their next-generation pancreatic cancer test, which were published on December 9, 2024.
The webcast will feature presentations from key company executives including CEO Jeff Borcherding, VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, and Laboratory Director Dr. Lisa Ford. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai, will provide additional perspective on the study outcomes.
The company focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million individuals are at high risk and could benefit from annual surveillance testing.
Immunovia (IMMNOV), un'azienda specializzata nella diagnostica del cancro pancreatico, ha annunciato un webcast programmato per il 17 dicembre 2024, alle 15:00 CET, per discutere i risultati positivi della validazione clinica del loro test innovativo per il cancro pancreatico, pubblicati il 9 dicembre 2024.
Il webcast presenterà interventi di importanti dirigenti dell'azienda, inclusi il CEO Jeff Borcherding, la VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, e il Direttore di Laboratorio Dr. Lisa Ford. La Dr.ssa Aimee Lucas, Capo di Gastroenterologia e Epatologia presso il Mount Sinai, fornirà ulteriori approfondimenti sui risultati dello studio.
L'azienda si concentra sullo sviluppo di test ematici per la rilevazione precoce del cancro pancreatico, mirando al mercato statunitense dove si stima che 1,8 milioni di individui siano ad alto rischio e possano beneficiare di controlli annuali.
Immunovia (IMMNOV), una empresa de diagnósticos del cáncer pancreático, anunció un webcast programado para el 17 de diciembre de 2024, a las 3 p.m. CET, para discutir los resultados positivos de la validación clínica de su prueba de cáncer pancreático de nueva generación, que se publicaron el 9 de diciembre de 2024.
El webcast contará con presentaciones de ejecutivos clave de la empresa, incluido el CEO Jeff Borcherding, la VP de Asuntos Clínicos y Médicos Dr. Norma Alonzo Palma, y la Directora de Laboratorio Dr. Lisa Ford. La Dra. Aimee Lucas, Jefa de Gastroenterología y Hepatología en Mount Sinai, proporcionará una perspectiva adicional sobre los resultados del estudio.
La empresa se centra en desarrollar pruebas basadas en sangre para la detección temprana del cáncer pancreático, dirigiéndose al mercado de EE.UU., donde se estima que 1,8 millones de individuos están en alto riesgo y podrían beneficiarse de pruebas de vigilancia anuales.
Immunovia (IMMNOV)는 췌장암 진단 회사로, 2024년 12월 17일 CET 오후 3시에 차세대 췌장암 검사의 긍정적인 임상 검증 결과를 논의하기 위한 웹캐스트를 예정했다고 발표했습니다. 이 결과는 2024년 12월 9일에 발표되었습니다.
웹캐스트에서는 CEO Jeff Borcherding, VP 임상 및 의료 업무 Dr. Norma Alonzo Palma, 실험실 이사 Dr. Lisa Ford 등 주요 회사 임원들의 발표가 있을 예정입니다. Mount Sinai의 위장병 및 간병 전문가인 Dr. Aimee Lucas가 연구 결과에 대한 추가적인 관점을 제공할 것입니다.
회사는 조기 췌장암 검출을 위한 혈액 기반 테스트 개발에 집중하고 있으며, 미국 시장을 목표로 하고 있습니다. 이곳에서는 180만 명이 높은 위험에 처해 있으며 연간 감시 검사를 통해 혜택을 받을 수 있을 것으로 추정됩니다.
Immunovia (IMMNOV), une entreprise de diagnostic du cancer du pancréas, a annoncé un webinaire prévu pour le 17 décembre 2024 à 15h CET afin de discuter des résultats positifs de la validation clinique de leur test de cancer du pancréas de nouvelle génération, publiés le 9 décembre 2024.
Le webinaire présentera des interventions de dirigeants clés de l'entreprise, notamment le PDG Jeff Borcherding, la VP des affaires cliniques et médicales Dr. Norma Alonzo Palma, et le directeur de laboratoire Dr. Lisa Ford. Dr. Aimee Lucas, responsable de la gastro-entérologie et de l'hépatologie au Mount Sinai, fournira une perspective supplémentaire sur les résultats de l'étude.
L'entreprise se concentre sur le développement de tests sanguins pour la détection précoce du cancer du pancréas, ciblant le marché américain où environ 1,8 million de personnes sont à haut risque et pourraient bénéficier de tests de surveillance annuels.
Immunovia (IMMNOV), ein Unternehmen für die Diagnostik von Bauchspeicheldrüsenkrebs, kündigte ein Webcast an, das für den 17. Dezember 2024 um 15 Uhr CET geplant ist, um die positiven klinischen Validierungsergebnisse ihres Tests der nächsten Generation für Bauchspeicheldrüsenkrebs zu diskutieren, die am 9. Dezember 2024 veröffentlicht wurden.
Das Webcast wird Präsentationen von wichtigen Unternehmensvertretern umfassen, darunter CEO Jeff Borcherding, VP für klinische und medizinische Angelegenheiten Dr. Norma Alonzo Palma und Laborleiterin Dr. Lisa Ford. Dr. Aimee Lucas, Leiterin der Gastroenterologie und Hepatologie am Mount Sinai, wird zusätzliche Perspektiven zu den Studienergebnissen bieten.
Das Unternehmen konzentriert sich darauf, blutbasierte Tests zur frühen Erkennung von Bauchspeicheldrüsenkrebs zu entwickeln, wobei der US-Markt im Fokus steht, wo schätzungsweise 1,8 Millionen Personen einem hohen Risiko ausgesetzt sind und von jährlichen Überwachungstests profitieren könnten.
- None.
- None.
Jeff Borcherding, CEO, Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs and Lisa Ford, PhD, Laboratory Director will present additional details about the results and the implications of the study. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai and Professor of Medicine Icahn School of Medicine, will join the webcast to share perspective on the study outcome. The webcast will be held in English and will offer attendees the opportunity to ask questions. You are welcome to join, see details below.
Link to the webcast: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71
A recording of the presentation will be available on Immunovia's website.
For more information, please contact:
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:SOURCE Immunovia AB
FAQ
When will Immunovia (IMMNOV) host its webcast on the new pancreatic cancer test results?
What is the market size for Immunovia's (IMMNOV) pancreatic cancer detection test in the USA?
Who are the key speakers at Immunovia's December 17 webcast?
When did Immunovia (IMMNOV) publish the clinical validation results for its next-generation pancreatic cancer test?
What is the main focus of Immunovia's (IMMNOV) diagnostic development?
